Yes, best in class would be based on response, duration of response, and safety profile. In resistant population, 378 and 113 have not separated on response and duration of response, there is some separation on grade 1/2 AEs which is not as important as first in class for terminal oncology indications IMO. In naive population, 802 has separated from 378 and 113 in response and duration of response somewhat for now, not much separation in safety profile. All in all, as I said, the three are close and competitive right now, might not have as big difference as many expect/hope eventually, it depends on expectation. I personally can't say at this moment which one would be winner which one would be loser, so my assumption is almost 3-way tie at the moment with 378 leading development timeline. I can always change my mind when more data come in.
